Status:
WITHDRAWN
ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)
Lead Sponsor:
Ophthotech Corporation
Conditions:
Idiopathic Polypoidal Choroidal Vasculopathy
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy
Eligibility Criteria
Inclusion
- Diagnosis of IPCV
- Patients must have had 3 sequential Eylea injections within the previous 4 months
Exclusion
- Intravitreal treatment in the study eye prior to screening, regardless of indication, except 3 prior injections of Eylea
- History or evidence of severe cardiac disease
- Any major surgical procedure within one month of trial entry
- Subjects with a clinically significant laboratory value
- Any treatment with an investigational agent in the past 60 days for any condition
- Women who are pregnant or nursing
- Known serious allergies to the fluorescein dye, ICG dye, iodine, povidone iodine, or to the components or formulation of either Zimura or Eylea
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03374670
Start Date
November 1 2018
End Date
December 1 2019
Last Update
February 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Consultants of Hawaii
‘Aiea, Hawaii, United States, 96701